Tuberculosis bacteria rely on a family of genes that help them survive the challenging journey from one person’s lungs to another person’s during coughing, sneezing or talking, according to researchers from Weill Cornell Medicine and the Massachusetts Institute of Technology. The findings provide new targets for tuberculosis therapies that could simultaneously treat infection and prevent the spread of bacteria. 

People with Crohn’s disease and related joint inflammation linked to immune system dysfunction have distinct gut bacteria or microbiota, with the bacterium Mediterraneibacter gnavus being a potential biomarker, according to new study by Weill Cornell Medicine researchers.

A new study unveils a precise picture of how an ion channel found in most mammalian cells regulates its own function with a “ball-and-chain” channel-plugging mechanism, according to investigators at Weill Cornell Medicine. The findings boost the understanding of ion channel biology and could lead to new drugs that target these channels to treat disorders such as epilepsy and hypertension.

Working toward more effective tuberculosis (TB) vaccines, researchers at Weill Cornell Medicine have developed two strains of mycobacteria with "kill switches" that can be triggered to stop the bacteria after they activate an immune response. Two preclinical studies, published, Jan. 10 in Nature Microbiology, tackle the challenge of engineering bacteria that are safe for use in controlled human infection trials or as better vaccines. While TB is under control in most developed countries, the disease still kills over a million people a year worldwide.

Adding engineered human blood vessel-forming cells to islet transplants boosted the survival of the insulin-producing cells and reversed diabetes in a preclinical study led by Weill Cornell Medicine investigators. The new approach, which requires further development and testing, could someday enable the much wider use of islet transplants to cure diabetes.

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, research led by Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center (MSK) and The Rockefeller University identified a vulnerability that opens the door to new treatments.

A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda.

The study, published Jan. 30 in the Journal of Antimicrobial Chemotherapy, adds to growing evidence that lenacapavir may be a powerful new tool in the global anti-HIV drug arsenal. Approximately, 1.5 million people are living with HIV in Uganda.

Two Weill Cornell Medicine physician-scientists, Dr. Niroshana Anandasabapathy and Dr. Rohit Chandwani, have been elected members of the American Society for Clinical Investigation (ASCI) for 2025.

Blood clots form in response to signals from the lungs of cancer patients—not from other organ sites, as previously thought—according to a preclinical study by Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center and University of California San Diego Health. Clots are the second-leading cause of death among cancer patients with advanced disease or aggressive tumors.

The distinct population of endothelial cells that line blood vessels in the insulin-producing “islets” of the human pancreas have been notoriously difficult to study, but Weill Cornell Medicine investigators have now succeeded in comprehensively detailing the unique characteristics of these cells. The resulting atlas advances basic research on the biology of the pancreas and could lead to new treatment strategies for diabetes and other pancreatic diseases.